Background: While a recent meta-analysis of observational studies reported a statistically significant association between sarcopenia and both all-cause mortality and functional decline, a recently developed inverse heterogeneity (IVhet) model has been shown to be more valid than the traditional random-effects model used. Objective: The objective of this short report was to use a previous meta-analysis to compare the two approaches. Methods: Aggregate data meta-analysis of prospective observational studies conducted in any setting. Men and women 60 years of age and older in which all-cause mortality (12 studies, 14,169 participants) or functional decline (6 studies, 8561 participants) was assessed. Using the IVhet model, pooling of previous studies regarding the association between sarcopenia and all-cause mortality as well as functional decline. Absolute and relative differences between IVhet and random-effects results were also calculated as well as influence analysis with each study deleted once. Non-overlapping 95% confidence intervals (CI) for odds ratios (OR) were considered statistically significant. Results: Sarcopenia was associated with an increased risk for all-cause mortality (OR = 3.64, 95% CI = 2.94 to 4.51) and functional decline (OR = 2.58, 95% CI = 1.33 to 4.99). Compared to the random-effects model, the OR was slightly higher (0.04 or 1.1%) but with wider CI (0.16 or 11.3%) for all-cause mortality and 0.45 (14.9%) lower with a CI that was 0.34 (10.2%) wider for functional decline. With each study deleted from the model once, results remained statistically significant for both all-cause mortality and functional decline. Conclusion: These results provide additional and more accurate evidence in support of an association between sarcopenia and an increased risk for both all-cause mortality and functional decline.
Introduction
Sarcopenia is a major public health problem worldwide. Depending on the definitions applied, the prevalence of sarcopenia has been reported to range between 5% and 13% in adults 60 to 70 years of age and 11% and 50% for those aged 80 and older (von Haehling et al., 2010) . In terms of costs, the direct healthcare costs attributed to sarcopenia in the United States in 2000 was estimated at $18.5 billion, $10.8 billion in men and $7.7 billion in women (Janssen et al., 2004) . This was estimated to account for approximately 1.5% of the total healthcare expenditures for that year (Janssen et al., 2004) . Given the aging population worldwide (United Nations DoEaSA, Population Division, 2015) , the absolute number of people with sarcopenia is also expected to increase.
Recently, Beaudart et al. (2017) , conducted a systematic review with meta-analysis on the association between sarcopenia and all-cause mortality as well as functional decline in adults 60 years of age and older. Overall, sarcopenia was reported to be associated with an increased risk, i.e., odds ratio (OR), for both all-cause mortality (OR = 3.60, 95% CI = 2.96 to 4.37) as well functional decline (OR = 3.03, 95% CI = 1.80 to 5.12) (Beaudart et al., 2017) . While these findings are noteworthy, they were derived using a conventional random-effects model (Dersimonian and Laird, 1986) . However, a recently developed and alternative approach, the inverse heterogeneity (IVhet) model (Doi et al., 2015) , has been shown to outperform the traditional random-effects model (Beaudart et al., 2017) . This includes greater preservation of coverage probabilities as well as a lower observed variance (Doi et al., 2015) .
Given the current and projected prevalence of sarcopenia and its potential deleterious consequences on both all-cause mortality and functional decline as well as the need to provide accurate overall estimates regarding the magnitude and dispersion of these associations, the Experimental Gerontology 96 (2017) 
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Experimental Gerontology j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / e x p g e r o purpose of this short report was to use the IVhet model (Doi et al., 2015) to examine the association between sarcopenia and all-cause mortality, as well as functional decline, and compare these findings with previous meta-analytic results based on the random-effects model (Beaudart et al., 2017) .
Methods

Data source
Data for this short report were derived from a recently published systematic review with meta-analysis on the association between sarcopenia and all-cause mortality as well as functional decline, details of which have been described elsewhere (Beaudart et al., 2017) . Briefly, studies were limited to those that defined sarcopenia according to the European Working Group on Sarcopenia in Older People (Cruz-Jentoft et al., 2010) . Twelve prospective studies that included 14,169 participants in which all-cause mortality was assessed and 6 studies representing 8561 participants in which functional decline was assessed, were pooled. All participants were 60 years of age and older, with the percentage of females ranging from 0% to 60% for all-cause mortality (Â ± SD = 52.6 ± 17.6, median = 56) and 0% to 63% for functional decline (Â ± SD = 48.4 ± 24.0, median = 56). Follow-up time, in years, ranged from 0.25 to 10 for all-cause mortality (Â ± SD = 4.1 ± 3.5, median = 4) and 0.25 to 10 for functional decline (Â ± SD = 4.1 ± 3.2, median = 4). The prevalence of sarcopenia for all-cause mortality studies ranged from 4.3% to 73.3% (Â ± SD = 26.5 ± 20.4, median = 22) and 4.3% to 58.0% for functional decline (Â ± SD = 17.4 ± 20.1, median = 10).
Data synthesis 2.2.1. Effect size calculations
The effect sizes pooled for the current study were extracted from previously reported OR results for sarcopenia and all-cause mortality as well as functional decline (Beaudart et al., 2017) .
Effect size pooling
The recently developed IVhet model (Doi et al., 2015) was used to pool OR results with respect to the presence of sarcopenia and resultant all-cause mortality and functional decline. This quasi-likelihood model is produced by calculating weights that sum to 1 from each study, pooling the effects from all studies, and then calculating the variance of the pooled effect sizes. This is accomplished as follows:
where, w j above are weights that sum to 1, and v j is the variance, followed byθ
whereθ IVhet above is the estimated pooled effect for changes in all-cause mortality and functional decline, followed by
where varðθ IVhet Þ above is the estimated variance of pooled effects for all-cause mortality or functional decline and τ 2 is the between-study variance. The IVhet model has been shown to be more valid then the original random-effects, method-of-moments model of Dersimonian and Laird (1986) , the most commonly used model for pooling aggregate data meta-analytic results (Dersimonian and Laird, 2015) . Specifically, simulation studies have demonstrated that the IVhet model maintains correct coverage probabilities and a lower observed variance than the random-effects model, irrespective of heterogeneity (Doi et al., 2015) .
The pooled results for all-cause mortality and functional decline derived from the IVhet model were then compared to those previously calculated using the original random-effects method-of-moments model of Dersimonian and Laird (Beaudart et al., 2017) . In addition, Q and I 2 statistics for heterogeneity and inconsistency were calculated as well as influence analysis with each study deleted from the model once. For I 2 , inconsistency was considered to be very low (b 25%), low (25% to b50%), moderate (50% to b75%) or large (≥ 75%) (Higgins et al., 2003) . All analyses were conducted using the log transformation and then back transformed to OR for presentation purposes. Analyses were performed using Meta XL, version 5.3 (EpiGear International, Queensland, Australia).
Results
A forest plot of for the association between sarcopenia and all-cause mortality is shown in Fig. 1 . Overall, sarcopenia was associated with an increased risk for all-cause mortality (OR = 3.64, 95% CI = 2.94 to 4.51). No statistically significant heterogeneity was observed (Q = 16.1, p = 0.14) and low inconsistency based on the mean for I 2 was found (I 2 = 31.5%, 95% CI = 0% to 65.4%). The IVhet model yielded an OR that was slightly higher (0.04 or 1.1%) and a 95% confidence interval that was wider (0.16 or 11.3%) than previously reported results using a random-effects model (Beaudart et al., 2017) . With each study deleted from the model once, IVhet results remained statistically significant across all deletions, ranging from an OR of 3.36 (95% CI, 2.70 to 4.18) to 3.93 (95% CI, 3.06 to 5.04). A forest plot of the results for the association between sarcopenia and functional decline is shown in Fig. 2 .
Overall, sarcopenia was associated with an increased risk for functional decline (OR = 2.58, 95% CI = 1.33 to 4.99). Statistically significant heterogeneity was observed (Q = 28.0, p b 0.001) and large inconsistency was found (I 2 = 82.1%, 95% CI = 62.1% to 91.6%). IVhet model results yielded an OR that was 0.45 (14.9%) lower and a 95% confidence interval that was 0.34 (10.2%) wider than the random-effects model (Beaudart et al., 2017) . With each study deleted from the model once, IVhet results remained statistically significant across all deletions, ranging from an OR of 2.29 (95% CI = 1.54 to 3.40) to 3.18 (95% CI = 1.54 to 6.56).
Discussion
This short report provides additional and more accurate information regarding the increased risk for all-cause mortality and functional decline in adults with sarcopenia, an increasing problem worldwide (von Haehling et al., 2010) . These findings are probably important for at least two reasons. First, the current results using the IVhet model provide more accurate information than the random-effects model, yielding wider confidence intervals for both all-cause mortality (11.3%) and functional decline (10.2%) as well a smaller odds ratio for functional decline (14.9%) given the large amount of heterogeneity observed. This is important for determining the true magnitude of the association between sarcopenia, all-cause mortality and functional decline. However, these findings are not surprising given the tendency for overly liberal findings when the random-effects versus IVhet model is used, especially when substantial heterogeneity is present (Doi et al., 2015) . More specifically, as heterogeneity increases, there is greater dispersion between the IVhet and random-effects model (Doi et al., 2015) . Thus, while there is little difference between the IVhet and random-effects results for mortality given the small amount of heterogeneity, there is an alternatively greater divergence in results for disability between the two models because of the large amount of heterogeneity (Doi et al., 2015) . As random effects weights become more equal with greater heterogeneity, the findings reduce to the arithmetic mean and thus, less robust estimates. For example, for the current disability results, the random effects weights differed by only 5.3% while the IVhet weights differed by 43.3%.
Second, the current findings suggest that caution may be warranted when interpreting any meta-analysis when a random-effects model is used to examine the association between sarcopenia and selected variables. This is important because meta-analyses are often considered to be at the hierarchy of the evidence-based pyramid, and thus, are often used to make decisions about the effects a condition such as sarcopenia on outcomes such as all-cause mortality and functional decline.
While the results of this study are important, they should be viewed with respect to the following potential limitations. First, since the current findings were based on aggregate data, there is the potential for ecological fallacy. Second, there was significant statistical heterogeneity and inconsistency for functional decline, regardless of the model used. As a result, and while beyond the scope of this brief report, there may be some subgroups in which the association between sarcopenia and functional decline, as well as all-cause mortality, may be different (Beaudart et al., 2017) . However, because studies are not randomly assigned to subgroups in meta-analysis, they are considered to be observational in nature. Therefore, the results of any subgroup analyses conducted in an aggregate data meta-analysis do not support causal inferences (Littell et al., 2008) . In addition, multiple subgroup analyses increase the risk for chance findings and are often limited to simple metaregression because of missing data for different variables from different studies.
In conclusion, the results of this short report provide additional and more accurate evidence in support of an association between sarcopenia and an increased risk for both all-cause mortality and functional decline. Future aggregate data meta-analyses should consider using the IVhet versus traditional random-effects model.
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